26 results
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
;
compliance with laws, including anti-corruption and anti-bribery laws;
regulatory matters;
environmental matters;
intellectual property and computer
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
of the Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery, anti-corruption, anti-money laundering, record keeping … that prohibits bribery, corruption, fraud, or other improper payments.
(c) Neither the Company, nor any of its officers, directors, employees, agents
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
of the Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery, anti-corruption, anti-money laundering, record keeping … that prohibits bribery, corruption, fraud, or other improper payments.
(c) Neither the Company, nor any of its officers, directors, employees, agents
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
systems and databases could result in unauthorized access to data and information and loss, compromise or corruption of such data and information … to be available to POINT on economically reasonable terms, or at all. POINT is subject to certain U.S. and foreign anti-corruption, anti-money laundering
424B3
PNT
POINT Biopharma Global Inc.
31 Mar 22
Prospectus supplement
11:42am
and information and loss, compromise or corruption of such data and information. Present and future CROs, contractors and consultants also could experience … .
POINT is subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations
POS AM
w1tbcav kdgb
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
q08s m1e7figj3db
5 Aug 21
Prospectus supplement
4:26pm
424B3
ihrwb
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
ytw8wgaz8aey7070
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.17
wobfzz8os e6
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
S-4
l22qya
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
hgdxezt 5y5t2f3
18 Mar 21
Financial Statements and Exhibits
9:08am
10-K
2dn93ue7bk
5 Mar 21
Annual report
8:13am
8-K
EX-1.1
zwe3kug8iivold0
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm
424B4
sum5fw
9 Jul 20
Prospectus supplement with pricing info
4:46pm